iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
These forward-looking statements are based upon current estimates and assumptions and include statements regarding non-human primate pharmacokinetics data suggesting IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days; remaining on track to submit a regulatory submission for IBIO-600 in Q1 2026; IBIO-600 providing a significantly extended half-life in humans and a weight loss treatment option while preserving and promoting muscle growth; the extended half-life potentially enabling a once every 3 to 6-month dosing schedule and positioning IBIO-600 as a best-in-class therapeutic for muscle preservation and high-quality weight loss; IBIO-600 possibly exhibiting the longest half-life among any other anti-myostatin candidates — potentially leading to best-in-class muscle preservation and growth with a significantly reduced dosing burden for patients with a few doses a year; IBIO-600’s extended half-life and muscle-building potential making it a transformative candidate for high-quality weight loss, further strengthening our expanding cardiometabolic and obesity pipeline; and the potential of Activin E inhibition as a transformative approach to obesity treatment, supporting further development and clinical advancement.
Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026 SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc.(Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced data from a non-GLP non-human primate (NHP) pharmacokinetics (PK) study suggesting IBIO-600, the company’s novel lead asset and a potentially best-in-class long-acting anti-myostatin antibody designed for subcutaneous administration, could provide a significantly extended half-life in humans and a weight loss treatment option while preserving and promoting muscle growth.
Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of IBIO-600 to have a half-life as long as 130 days; the ability of iBio’s innovative pipeline of therapeutics in cardiometabolic disease and obesity to promote healthy weight loss and muscle-building; and iBio’s ability to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; iBio’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio’s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio’s product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio’s filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2024 and its subsequent filings with the SEC on Forms 10-Q and 8-K.
The story "iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline" has 1213 words across 28 sentences, which will take approximately 6 - 11 minutes for the average person to read.
Which news outlet covered this story?
The story "iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline" was covered 15 hours ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 53 news stories per day.
It's most recent story was published 9 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Negative, indicating that people regard this as "bad news".
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
